Sleep disordered breathing (SDB) appears to be common
|
|
- Meagan Gilbert
- 8 years ago
- Views:
Transcription
1 The Current Prevalence of Sleep Disordered Breathing in Congestive Heart Failure Patients Treated with Beta-Blockers Mary Macdonald, RPSGT; James Fang, M.D.; Steven D. Pittman, MSBME; David P. White, M.D.; Atul Malhotra, M.D. Divisions of Cardiovascular Diseases, Sleep Medicine, and Pulmonary and Critical Care Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Study Objectives: Although sleep disordered breathing is thought to be common in patients with systolic heart failure, prior studies are difficult to interpret due to a variety of factors including small sample sizes, referral bias to sleep laboratories among participants, lack of modern medical therapy for congestive heart failure, and the failure to use modern techniques to assess breathing such as nasal pressure. Our objective was to determine the current prevalence of sleep disordered breathing in a state-of-the-art congestive heart failure clinic. Methods: We conducted a prospective study of consecutive patients who visited our heart failure clinic to assess the prevalence of sleep apnea in all eligible patients on maximal medical therapy. We used 4-channel recording equipment and modified Chicago criteria for scoring respiratory events (using heart rate response as a surrogate for arousal from sleep). Results: We observed that among the 108 participants, 61% had some form of sleep disordered breathing (31% central apnea with Cheyne Stokes respiration and 30% obstructive sleep apnea). Sleep Scientific investigations disordered breathing was significantly associated with atrial fibrillation (OR = 11.56, p = 0.02) and worse functional heart failure class (OR = 2.77, p = 0.02), after adjusting for male sex, age over 60 years, body mass index, and left ventricular ejection fraction. Conclusions: We conclude that both obstructive and central sleep apnea remain common in congestive heart failure patients despite advances in medical therapy, and that the previously reported high prevalence values are unlikely to be explained by referral bias or participation bias in prior studies. These data have important clinical implications for practitioners providing CHF therapy. Keywords: Apnea, sleep, congestive heart failure, obstructive, central, outcome, lung Citation: Macdonald M; Fang J; Pittman SD; White DP; Malhotra A. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. J Clin Sleep Med 2008;4(1): Sleep disordered breathing (SDB) appears to be common among patients with congestive heart failure (CHF). 1,2 Prior studies have suggested that 40%-50% of patients with CHF and left ventricular systolic dysfunction will have some form of SDB, either obstructive or central sleep apnea (CSA). 1-3 However, important limitations exist in these previous reports. Many were based in sleep laboratories and therefore subject to referral and participatory bias. 2 To our knowledge, only one study, using nonconsecutively enrolled subjects, has prospectively Disclosure Statement This study was supported in part by Respironics. Dr. White is employed by Respironics and has received research and consulting fees from Itamar Medical and consulting fees from Aspire Medical. Dr. Malhotra has received research support from Respironics, Inspiration Medical, NMT Medical, Restore Medical, Pfizer, and Cephalon. Dr. Fang and Ms. Macdonald have indicated no financial conflicts of interest. Mr. Pittman is an employee of Respironics. Submitted for publication June, 2007 Accepted for publication October, 2007 Address correspondence to: Atul Malhotra, Sleep Disorders Research BIDMC, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115; Tel: (617) ; Fax: (617) ; amalhotra1@partners.org evaluated the prevalence of SDB in outpatients in a heart failure clinic. 4 Other studies have been limited by technical issues such as the use of respiratory monitoring systems that do not employ state-of-the-art sensors for ventilation i.e., nasal pressure to assess hypopneas. 5 Previous studies have also been difficult to reconcile due to variable definitions of CSA, and a failure to distinguish between CSA in general and Cheyne Stokes respiration (CSR) in particular. In many cases, it can be difficult to distinguish obstructive from central apnea type in CHF patients, leading some authors to suggest that different metrics for sleep disordered breathing severity may be desirable. 6 Perhaps most importantly, many previous studies have not included study populations with currently optimal medical management including adequately dosed β-blockers, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor antagonists (ARBs) and aldosterone antagonists. 7 This lack of optimized medical therapy may have particular relevance since such therapies may have an impact on the prevalence of SDB such as CSR. 8,9 For example, β-blockers are known to influence hypoxic chemosensitivity which would be predicted to influence the development of CSR. 10,11 Similarly, ACEI and diuretic therapy can both contribute to lower intracardiac filling pressures, which could importantly influence the occurrence of CSR. 8,12 The goals of this study were to (1) prospectively evaluate the prevalence of SDB in consecutive medically optimized outpa- Journal of Clinical Sleep Medicine, Vol. 4, No. 1,
2 Table 1 Baseline Clinical Characteristics of Study Participants and Non-Participants* Participants Non-Participants p value (n=108) (n=45) Female n,% 16 (15) 14 (31) 0.04 Age (yr) 57 ± ± BMI (kg/m 2 ) 26.8 ± ± LVEF, % 20 (15-30) 20 (15-25) 0.89 Class II 67 (62) 27 (60) Class III-IV 41 (38) 18 (40) 0.96 Ischemic 47 (44) 26 (58) Idiopathic 61 (66) 19 (42) 0.15 β-blockers n,% 39 (82) 39 (86) 0.68 Other Medications, % Loop diuretics 88 ** ACE inhibitor 83 ** Digitalis 63 ** Anticoagulant 48 ** Spironolactone 36 ** Statin 35 ** Antiplatelet 34 ** Antiarrhythmic 30 ** Nitrate 25 ** ARB 13 ** AHI (/h) 24.7 ±17.2 ** CSR time, % 24 ±30 ** Atrial fibrillation n, % 15 (14) ** *Unless indicated, values expressed as mean ±SD or median (95% CI range) ** not compared tients in a heart failure clinic; (2) examine risk factors for SDB and specifically CSR in this population; and (3) explore alternative metrics for CSR. METHODS One hundred and eight subjects out of 153 consecutively eligible patients from the Heart Failure Clinic of the Brigham & Women s Hospital agreed to participate. Prior to enrollment, subjects were not asked about symptoms or risk factors for SDB. Subjects were included if they had clinically stable heart failure; were between the ages of 18 and 85 years; had New York Heart Association (NYHA) functional class II, III, or IV; and had a left ventricular ejection fraction (LVEF) of <40%. Subjects were excluded if they had primary valvular heart disease, primary diastolic failure (i.e., congestive heart failure with normal systolic function), a history of major lung disease (i.e., obstructive pulmonary disease), a history of pneumothorax in the prior 6 months, current or previous use of positive airway pressure noninvasive ventilation, current use of supplemental oxygen, or the presence of an artificial airway. Subjects who had been hospitalized or had medication changes within the past 30 days were also excluded. All subjects provided written informed consent. This study was approved by the Partners Institutional Review Board. Subjects underwent echocardiographic assessment of LVEF 12 months prior to performing a sleep study, during which time LVEF was unlikely to significantly change, Sleep Apnea in Heart Failure Table 2 Clinical Characteristics of Subjects with and without Sleep Disordered Breathing* no SDB SDB p value (n=42) (n=66) Prevalence 39% 61% Female n,% 7 (17) 9 (14) 0.88 Age (yr) 56 ±9 58 ± BMI (kg/m 2 ) 26.8 ± ± AHI (/h) 9.5 ( ) 32.9 ( ) <0.001 CSR time, % 0 (0-7) 34 (9-72) <0.001 LVEF, % 20 (15-25) 20 (15-30) 0.29 Class II 31 (74) 36 (55) Class III-IV 11 (26) 30 (45) 0.07 Ischemic 15 (36) 32 (49) Idiopathic 27 (64) 34 (51) 0.27 β-blockers n, % 39 (93) 50 (77) 0.06 Atrial fibrillation n, % 1 (2) 14 (21) 0.01 *Unless indicated, values expressed as mean ±SD or median (95% CI range) since a repeat echocardiogram is performed if any important change in clinical status occurs. All echocardiograms were read by board certified cardiologists with advanced training in echocardiography. The Teichholz formula is routinely used to assess LVEF, which must be agreed upon by the overreading echocardiographer. Subjects underwent an in-home, unattended overnight study with a standard 4-channel recording device (StarDust, Respironics, Inc, Murrysville, PA). This device records nasal pressure, thoracic excursion (as measured by a piezoelectric crystal), body position, pulse oximetry, and heart rate derived from pulse oximetry. The data were downloaded and scored by an experienced scorer. A modified version of the 1999 American Academy of Sleep Medicine (AASM) criteria for scoring respiratory events was used. 13,14 An obstructive apnea was defined as 10-sec cessation of airflow as measured by nasal pressure associated with the continuation of thoracic effort. A central apnea was defined as 10-sec cessation of airflow without thoracic effort. A hypopnea was defined as a 50% reduction in airflow for 10 sec or a discernable change in airflow with either a 3% oxyhemoglobin desaturation or an arousal, as defined by a 10% increase in heart rate. 15 Arousal was defined based on a 10% change in heart rate because EEG was not available using the StarDust system. We believe that a relative rather than absolute change in heart rate is more reliable for comparing patients with and without β-blockade. The apnea-hypopnea index (AHI) and central apnea index (CAI) were calculated based on total number of events per hour of total recording time (TRT). SDB was defined by AHI of 15 events per hour. Another metric of CSR was also used for exploratory purposes. In this case, CSR was defined as a symmetrical crescendo-decrescendo respiratory pattern with a >50% difference between peak and nadir nasal pressure or respiratory effort amplitude, occurring within a 30 to 90-second period. Primary CSR was defined as a study with a CSR time (as a percentage of total recording time) 33%. Primary OSA was predefined as an AHI 15 events per hour and a CSR time of <33%. Journal of Clinical Sleep Medicine, Vol. 4, No. 1,
3 M Macdonald, J Fang, S Pittman et al Table 3 Clinical Characteristics of Subjects with and without Cheyne Stokes Respiration* no CSR CSR p value (n=74) (n=34) Prevalence 69% 31% Female n, % 13 (18) 3 (9) 0.37 Age (yr) 56 ± ± BMI (kg/m 2 ) 27.0 ± ± AHI (/h) 13.6 ( ) 37.8 ( ) <0.001 CSR time, % 3.1 ( ) 68.6 ( ) <0.001 LVEF, % 24 (15-30) 15 (13-25) 0.02 Class II 52 (70) 15 (44) Class III-IV 22 (30) 19 (56) 0.02 Ischemic 31 (66) 16 (47) Idiopathic 43 (34) 18 (53) 0.77 β-blockers n,% 66 (89) 23 (68) 0.49 Atrial fibrillation n, % 6 (8) 9 (26) 0.02 *Values expressed as mean ±SD or median (95% CI range) Differences between groups were assessed using the unpaired Student s t-test for parametric results and the Mann-Whitney rank sum test for nonparametric data. χ 2 was used to compare proportions between groups. Logistic regressions were used to assess the odds ratios of SDB, and CSR, conferred by various independent variables. A value of p < 0.05 was considered statistically significant, with results being reported as the mean ± SD or median and 95% confidence intervals. Candidate independent variables were first established using a univariate model. The final model included only those variables with a significant effect on the dependent variable as measured by the likelihood ratio test statistic (p < 0.05). Multiple logistic regression was then used to establish the multivariate variables that remained independently predictive of SDB and CSR. The same regression model was also used to determine if the self-reported use of β-blockers independently predicted the presence or absence of SDB and CSR Odds ratios and 95% confidence intervals were calculated. Calculations were performed in SigmaStat 3.0 software. RESULTS 108 subjects (92 males and 16 females) enrolled in the study (participation rate of 71%). The primary reason for refusal to participate was the perceived inconvenience of the in-home sleep study. Other than a higher proportion of females among the nonenrolled, there were no significant baseline clinical differences between those who enrolled and those who did not (see Table 1). Sleep Disordered Breathing The prevalence of SDB in this cohort was 61% (57 males and 9 females). 31% of subjects had primary CSR (31 males and 3 females); 30% had primary OSA (26 males and 6 females). Between the groups with and without SDB (Table 2), the only significant difference was the presence of atrial fibrillation in the SDB group (21% vs. 2%, p = 0.01). There were no significant differences in baseline demographics, NYHA class, LVEF, CHF etiology, or β-blocker use. Figure 1 The prevalence of Cheyne Stokes Respirations (CSR) varies with the definition used. With a rising threshold for percentage of CSR time, there is a falling prevalence of this breathing abnormality. At a cutoff of 33% CSR time, almost one third of participants had this disease. After adjusting for male sex, age over 60 years, BMI, and LVEF, subjects with SDB had a nearly 12-fold increased odds for atrial fibrillation (OR = 11.56, 95% CI , p = 0.02), and a significantly greater odds for a worse functional class of heart failure (OR = 2.77, 95% CI , p = 0.02). Cheyne Stokes Respiration The group with CSR time 33% had a mean CSR time of 68.6% ( ); the group without CSR had mean CSR time 3.1% ( ) (Table 3, Figure 1).The CSR group had significantly more impaired functional capacity than the group without CSR (NYHA class III-IV 44% vs 30% class II, p = 0.02), a lower LVEF (15% [ ] vs. 25% [ ], p = 0.02), and had more subjects with atrial fibrillation (26% vs. 8%, p = 0.02). There were no significant differences in baseline demographics, CHF etiology, or β-blocker use. After adjusting for male sex, age over 60 years, BMI, and LVEF, subjects with CSR had a nearly 6-fold increased odds for atrial fibrillation (OR = % CI , p = 0.01), and a significantly greater odds for a worse functional class of heart failure (OR = % CI , p = 0.01). Using a CAI cut-off of 5/h and 15/h respectively (consistent with definitions of primary CSA used in previous studies), 10,16 the prevalence of CSA in our group is 28% and 17%. NYHA functional class and the presence of atrial fibrillation still emerge as significant differences between those with CAI 15 and those with a CAI <15/h. (NHYA: 61% Class III-IV vs. 33%, p = 0.05; a. fib: 39% vs. 9% p = 0.003). β-blocker use was not significantly different between groups. β-blocker Usage Eighty-two percent of all subjects were using β-blockers (Table 4). The group not using β-blockers was significantly more functionally impaired than the group that was (63% Class III-IV vs. 33% Class III-IV, p = 0.03). There were no other significant differences in baseline demographics, severity of SDB, CHF eti- Journal of Clinical Sleep Medicine, Vol. 4, No. 1,
4 Table 4 Clinical Characteristics of Subjects on and off Blockers* Β-Blockers no β-blockers p value (n=89) (n=19) Prevalence 82% 18% Female n, % 11 (12) 5 (26) 0.23 Age (yr) 57 ± ± BMI (kg/m 2 ) 28.1 ± ± AHI (/h) 19.4 ( ) 31.8 ( ) 0.06 CSR time, % 9.0 ( ) 17.1 ( ) 0.36 LVEF, % 20 (15-30) 25 (15-30) 0.56 Class II 60 (67) 7 (37) Class III-IV 29 (33) 12 (63) 0.03 Ischemic 38 (43) 9 (47) Idiopathic 51 (57) 10 (53) 0.91 Atrial fibrillation n, % 10 (11) 5 (26) 0.17 * Values expressed as mean ±SD or median (95% CI range) ology, or the presence of atrial fibrillation; 77% of subjects with SDB and 68% with CSR were using β-blockers. After adjusting for male sex, age over 60, BMI, and LVEF, β-blocker use did not independently predict the presence or absence of SDB or CSR. Discussion In this heart failure clinic-based study of SDB in a cohort of unselected consecutive patients with CHF who were receiving optimally dosed medical management with both β-blockade and renin-angiotensin system antagonists, a high prevalence of SDB persisted (61% overall; 31% CSR and 30% OSA) supporting previous work suggesting that SDB is common in CHF. Our data add to the existing literature by showing that the previously reported prevalence rates are not likely a product of selection bias or a result of inadequate or antiquated medical therapy. Although β-blocker therapy in heart failure is associated with improvements in LVEF, functional class, and survival, it did not appear to affect the prevalence of SDB in our cohort, which was almost uniformly treated with these agents. In fact, the prevalence of SDB in this study is similar to the rates previously reported in other heart failure cohorts, which range from 41% to 75%. In these previous studies, β-blocker use was either not reported or limited to a minority of participants. In one of the only recent true prevalence studies where β-blocker therapy was reported, only 30% of heart failure patients were on these agents. 4 Furthermore, this prior study was limited to 53 subjects referred to a sleep laboratory with less advanced heart failure (NYHA I/II 75%, mean LVEF 34%). Thus, it would appear that newer therapies for CHF do not have a clinically important impact on overall breathing instability. However, because different criteria have been used to define the apnea hypopnea index in each of these studies, further work is clearly needed to determine if variations in prevalence reported in the literature are methodological or biological. Patients with both SDB (61%) and CSR (31%) were both more likely to have atrial fibrillation and poorer NYHA functional class than those without SDB or CSR. These differences were not explained by differences in demographic variables, medical therapy, or CHF etiology. Although previous studies have identified the association of atrial fibrillation with SDB Sleep Apnea in Heart Failure Table 5 Clinical Characteristics of Subjects with Cheyne Stokes Respiration vs. Obstructive Sleep Apnea* CSR OSA p value (n=34) (n=32) Prevalence 31% 30% Female n, % 3 (9) 6 (6) 0.3 Age (yr) 59 ± ± BMI (kg/m 2 ) 28.5 ± ± AHI (/h) 37.8 ( ) 26.0 ( ) <0.001 CSR time, % 68.6 ( ) 8.9 ( ) <0.001 LVEF, % 15 (13-25) 30 (20-32) Class II 15 (44) 21 (58) Class III-IV 19 (56) 11 (34) 0.13 Ischemic 16 (47) 16 (50) Idiopathic 18 (53) 16 (50) 0.99 β-blockers n,% 23 (68) 24 (75) 0.89 Atrial fibrillation n,% 9 (26) 5 (16) 0.44 *Values expressed as mean ±SD or median (95% CI range) and CSR, an association between NYHA functional class and CSR has not been previously reported to our knowledge. Although this finding would support the notion that CSR is a consequence of progressive heart failure, and in fact patients in our cohort with CSR had significantly lower LVEFs than those without CSR, the lack of a β-blocker interaction in this study may suggest otherwise. Another interpretation of these findings is that aggressive medical management of CHF may improve LVEF in some patients, whereas a persistently low LVEF may be a marker of a particularly impaired cardiovascular system. This impairment could manifest as an elevated filling pressure which could lead to CSR. 9 In addition, as seen in Table 5, there are some possible differences between those patients with CSR compared with those with OSA. OSA patients had lower AHI as well as higher LVEF as compared to those with CSR. However, β-blocker use did not differ between these groups. One limitation of our study is the use of a four-channel recording device that does not measure sleep. Thus, our measurements of AHI, CAI, and CSR time are based on total recording time rather than total sleep time (TST). This issue may be relevant in heart failure since sleep efficiency is often low. However, TRT may also be useful (in addition to TST), since many subjects experience CSR while awake. Furthermore, although it is recognized that sleep efficiency is low in heart failure, patients were studied at home (using a minimally invasive device) rather than in the sleep laboratory and therefore sleep efficiency may have been better than previous reports would indicate. Because our goal was to assess a large group of patients in a CHF clinic, we believe that our use of home monitoring allowed us access to the largest and most representative group possible. We have previously tried to refer all CHF patients for overnight inlaboratory polysomnography, but only the most motivated patients were willing to undergo this test. Thus, although our use of home monitoring is a potential limitation, it may have helped us access a more generalizable sample of heart failure patients. Sensitivity in our study was also optimized by using nasal pressure rather than thermistry as in some of the prior reports. In conclusion, SDB and CSR remain highly prevalent in subjects with CHF despite optimization of medical therapy. This Journal of Clinical Sleep Medicine, Vol. 4, No. 1,
5 M Macdonald, J Fang, S Pittman et al observation suggests that the relationship between SDB and heart failure is still poorly understood since effective therapies for heart failure appear to have no major effect on SDB. Because available evidence suggests that CSR may contribute to the progression of heart failure, 20 CSR may still represent a potential target of therapy for the persistently symptomatic patient on optimal medical therapy REFERENCES 1. Javaheri S, Parker TJ, Wexler L, et al. Occult sleep-disordered breathing in stable congestive heart failure [published erratum appears in Ann Intern Med 1995 Jul 1;123(1):77]. Ann Intern Med 1995;122: Sin D, Fitzgerald F, Parker J. et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am. J. Respir. Crit. Care Med. 1999;160: Christ M, Sharkova Y, Fenske H, et al. Brain natriuretic peptide for prediction of Cheyne-Stokes respiration in heart failure patients. Int J Cardiol 2007;116: Ferrier K, Campbell A, Yee B, et al. Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure. Chest 2005;128: Hosselet JJ, Norman RG, Ayappa I, Rapoport DM. Detection of flow limitation with a nasal cannula/pressure transducer. Am J Respir Crit Care Med 1998;157: Pack AI, Goldberg LR. Routine polysomnography is not indicated in congestive heart failure. Con. J Clin Sleep Med 2005;1: Sin D, Logan A, Fitzgerald F, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000;102: Solin P, Bergin P, Richardson M, Kaye DM, Walters EH, Naughton MT. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 1999;99: Lloyd TC, Jr. Effect of increased left atrial pressure on breathing frequency in anesthetized dog. J Appl Physiol 1990;69: Witte KK, Thackray S, Nikitin NP, Cleland JG, Clark AL. The effects of long-term betablockade on the ventilatory responses to exercise in chronic heart failure. Eur J Heart Fail 2005;7: Warner MM, Mitchell GS. Role of catecholamines and beta-receptors in ventilatory response during hypoxic exercise. Respir Physiol 1991;85: Solin P, Roebuck T, Johns DP, Walters EH, Naughton MT. Peripheral and central ventilatory responses in central sleep apnea with and without congestive heart failure. Am. J. Respir. Crit. Care Med. 2000;162: Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles: Brain Information Service/Brain Research Institute, UCLA, AASM. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in adults. Sleep 1999;22: Pitson DJ, Stradling JR. Autonomic markers of arousal during sleep in patients undergoing investigation for obstructive sleep apnoea, their relationship to EEG arousals, respiratory events and subjective sleepiness. J Sleep Res 1998;7: Malhotra A, Berry R, White D. Central sleep apnea. In: Carney PR, Berry RB, Geyer JD, Clinical Sleep Disorders. Philadelphia: Lippincott Williams & Wilkins, 2005: Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003;289: Krum H, Mohacsi P, Katus HA, et al. Are beta-blockers need- ed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Am Heart J 2006;151: Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;99: Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005;353: Eckert DJ, Jordan AS, Merchia P, Malhotra A. Central sleep apnea: Pathophysiology and treatment. Chest 2007; 131: Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006;173: Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 2000;101: Malhotra A, Muse VV, Mark EJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case An 82-year-old man with dyspnea and pulmonary abnormalities. New England Journal of Medicine 2003;348: Journal of Clinical Sleep Medicine, Vol. 4, No. 1,
Nocturnal Oxygen Therapy in the Management of Mild Cheyne-Stokes Respiration in Stable Congestive Heart Failure
Nocturnal Oxygen Therapy in the Management of Mild Cheyne-Stokes Respiration in Stable Congestive Heart Failure Joseph Lewarski BS, RRT, FAARC Robert Messenger BS, RRT Nocturnal Oxygen Therapy in the Management
More informationDiseases and Health Conditions that can Lead to Daytime Sleepiness
October 21, 2014 Diseases and Health Conditions that can Lead to Daytime Sleepiness Indira Gurubhagavatula, MD, MPH Associate Professor Director, Occupational Sleep Medicine University of Pennsylvania,
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationRisk Factors for Central and Obstructive Sleep Apnea in 450 Men And Women with Congestive Heart Failure
Risk Factors for Central and Obstructive Sleep Apnea in 450 Men And Women with Congestive Heart Failure DON D. SIN, FABIA FITZGERALD, JOHN D. PARKER, GARY NEWTON, JOHN S. FLORAS, and T. DOUGLAS BRADLEY
More informationUnderwriting Sleep Apnea
Underwriting Sleep Apnea Joel Weiner, MD, FLMI April 29, 2014 WAHLU The Northwestern Mutual Life Insurance Company Milwaukee, WI A Brief Survey Before We Get Started The Weiner Sleepiness Scale How likely
More informationHEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE
HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE The following diagnostic tests for Obstructive Sleep Apnea (OSA) should
More informationDoes Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD
Does Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD Background Obstructive Sleep Apnea(OSA) Obstructive sleep apnea (OSA)
More informationAccuracy of Auto-Titrating CPAP to Estimate the Residual Apnea-Hypopnea Index in Patients
0 Title: Accuracy of Auto-Titrating CPAP to Estimate the Residual Apnea-Hypopnea Index in Patients with Obstructive Sleep Apnea on Treatment with Auto-Titrating CPAP. Authors: Himanshu Desai M.D., Anil
More informationRaising Sleep Apnea Awareness:
Raising Sleep Apnea Awareness: Among People with Diabetes in North Carolina, 2012 People with diabetes have more sleep problems than people without diabetes in the same age, sex, and race/ethnicity group.
More informationUniversitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1
Test Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Heart Failure - Definition European Heart Journal (2008) 29, 2388 2442 Akute Herzinsuffizienz Diagnostik und
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationObstructive sleep apnea and type 2 diabetes Obstructive Sleep Apnea (OSA) may contribute to or exacerbate type 2 diabetes for some of your patients.
Obstructive sleep apnea and type 2 diabetes Obstructive Sleep Apnea (OSA) may contribute to or exacerbate type 2 diabetes for some of your patients. Prevalence of OSA and diabetes Prevalence of OSA Five
More informationPolysomnography in Patients with Obstructive Sleep Apnea. OHTAC Recommendation. Polysomnography in Patients with Obstructive Sleep Apnea
OHTAC Recommendation Polysomnography in Patients with Obstructive Sleep Apnea June 16, 2006 1 The Ontario Health Technology Advisory Committee (OHTAC) met on June 16, 2006 and reviewed a health technology
More informationPAP Therapy Devices: Delivering the Right Therapy To The Right Patient. Ryan Schmidt, BS,RRT Clinical Specialist Philips Respironics
PAP Therapy Devices: Delivering the Right Therapy To The Right Patient Ryan Schmidt, BS,RRT Clinical Specialist Philips Respironics Conflict of Interest Disclosure(s) I do not have any potential conflicts
More informationMaharashtra University of Health Sciences, Nashik. Syllabus. Fellowship Course in Sleep Medicine
Maharashtra University of Health Sciences, Nashik Syllabus Fellowship Course in Sleep Medicine Appendix A a) Title of the Fellowship Course: Fellowship Course in Sleep Medicine b) Duration of Course: 1
More informationA simple solution for your complex patients. The market-leading servo ventilation device System One BiPAP autosv
A simple solution for your complex patients The market-leading servo ventilation device System One BiPAP autosv Advanced simplifies treating complex sleep-disordered breathing patients Developed for your
More informationWhat is sleep apnea? 2/2/2010
Outline Nocturia and Sleep Apnea R. Keith Huffaker, MD Introduction Background & Incidence Definitions Differential Diagnosis of Nocturia Risk Factors of OSA Mechanism of OSA-Nocturnal Polyuria Diagnosis
More informationDiagnosis and Treatment
Sleep Apnea: Diagnosis and Treatment Sleep Apnea Sleep Apnea is Common Dangerous Easily recognized Treatable Types of Sleep Disordered Breathing Apnea Cessation of airflow > 10 seconds Hypopnea Decreased
More informationTherapeutic options for the treatment of Cheyne-Stokes respiration
Review article Peer reviewed article SWISS MED WKLY 2009;139(9 10):135 139 www.smw.ch 135 Therapeutic options for the treatment of Cheyne-Stokes respiration Winfried J. Randerath Institute of Pneumology
More informationPaul Wylie, MD 1, Sukhdev Grover, MD 2 1 Arkansas Center for Sleep Medicine, Little Rock AR; 2 Sleep Center of Greater Pittsburgh, Pittsburgh, PA
Automatic Bi-level Positive Airway Pressure Delivery with Flow-Directed Pressure Modulation and Expiratory Pressure Relief an In-laboratory Comparison with Conventional Bi-level Positive Airway Pressure
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationOut of Center Sleep Testing and Auto-titrating CPAP: Gizmos and Gadgets. Kathleen Sarmiento, MD NAMDRC 2014
Out of Center Sleep Testing and Auto-titrating CPAP: Gizmos and Gadgets Kathleen Sarmiento, MD NAMDRC 2014 DISCLOSURE Dr. Sarmiento has received research grants from Philips Respironics and ResMed, these
More informationCPAP titration: PSG technologist or at Home
CPAP titration: PSG technologist or at Home Carolyn D Ambrosio, MD, MS Associate Professor of Medicine Director, The Center for Sleep Medicine Tufts Medical Center Conflict of Interest No financial interest
More informationMODULE. POSITIVE AIRWAY PRESSURE (PAP) Titrations
MODULE POSITIVE AIRWAY PRESSURE (PAP) Titrations POSITIVE AIRWAY PRESSURE (PAP) TITRATIONS OBJECTIVES At the end of this module the student must be able to: Identify the standards of practice for administering
More informationChapter 17 Medical Policy
RAD-1 LCD for Respiratory Assist Devices (L11482) Contractor Information Contractor Name Contractor Number 00635 Contractor Type LCD Information LCD Database ID Number L11482 AdminaStar Federal, Inc. DMERC
More informationProceedings of the International MultiConference of Engineers and Computer Scientists 2009 Vol I IMECS 2009, March 18-20, 2009, Hong Kong
Pairwise Classifier Approach to Automated Diagnosis of Disorder Degree of Obstructive Sleep Apnea Syndrome: Combining of AIRS and One versus One (OVO-AIRS) K. Polat, S. Güneş, and Ş. Yosunkaya Abstract
More informationScientific investigations
Scientific investigations Persistence of Obstructive Sleep Apnea After Surgical Weight Loss Christopher J. Lettieri, M.D. 1,2 ; Arn H. Eliasson, M.D. 1,2 ; David L. Greenburg, M.D. 2,3 1 Pulmonary, Critical
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationChildren Who Snore Do they have Sleep Apnea? Iman Sami, M.D. Division of Pulmonary and Sleep Medicine, Children s National
Children Who Snore Do they have Sleep Apnea? Iman Sami, M.D. Division of Pulmonary and Sleep Medicine, Children s National June 3, 2015 No disclosures relevant to this talk No disclosures relevant to this
More informationRapid Resolution of Intense Suicidal Ideation after Treatment of Severe. From the Department of Psychiatry and Psychology (L.E.K.
Category [Case Report] Rapid Resolution of Intense Suicidal Ideation after Treatment of Severe Obstructive Sleep Apnea Lois E. Krahn, MD Bernard W. Miller, RPSGT Larry R. Bergstrom, MD From the Department
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationChanges in the Evaluation and Treatment of Sleep Apnea
Changes in the Evaluation and Treatment of Sleep Apnea Joseph DellaValla, MD FACP Medical Director Center for Sleep Medicine At Androscoggin Valley Hospital Sleep Related Breathing Problems Obstructive
More informationRestoring a good night s sleep
Restoring a good night s sleep Products for diagnosing, treating, and monitoring sleep apnea Sleep apnea solutions A good night s sleep is an essential part of healthy living, but for patients diagnosed
More informationNon-Invasive Risk Predictors in (Children with) Pulmonary Hypertension
Ideal risk prognosticator Easy to acquire Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Safe -- Non-invasive Robust Gerhard-Paul Diller Astrid Lammers Division of Adult Congenital
More informationCPAP Treats Muscle Cramps in Patients with Obstructive Sleep Apnea
CPAP Treats Muscle Cramps in Patients with Obstructive Sleep Apnea Andrew J Westwood, M.D., MRCP(UK) 1, Andrew R Spector, M.D., 2 Sanford H Auerbach, M.D. 3 1 Columbia University College of Physicians
More informationCompliance Issues in Home CPAP Therapy. Joseph Lewarski, BS, RRT, FAARC
Compliance Issues in Home CPAP Therapy Joseph Lewarski, BS, RRT, FAARC Obstructive Sleep Apnea Syndrome OSA 1 st recognized over 30 years ago 1981 Sullivan publishes small study in Lancet¹ Late 80s, early
More informationSummary of AASM Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea - Updated July 2012
Summary of AASM Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea - Updated July 2012 SUMMARY: Sleep technologists are team members who work
More informationSleep Apnea in Stroke. Diagnosis, Consequences & Treatment J.A. Aaronson
Sleep Apnea in Stroke. Diagnosis, Consequences & Treatment J.A. Aaronson SLEEP APNEA IN STROKE: SUMMARY The overall objective of this thesis was to improve our understanding of the effects of obstructive
More informationUpdate on Home Sleep Studies Is there a Home for Portable Monitoring?
Update on Home Sleep Studies Is there a Home for Portable Monitoring? Samuel T. Kuna, MD Center for Sleep and Respiratory Neurobiology University of Pennsylvania and Pulmonary, Critical Care & Sleep Section
More informationINHERIT. The Lancet Diabetes & Endocrinology In press
INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn
More informationPULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana
PULMONARY HYPERTENSION Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana What is Pulmonary Hypertension? What is normal? Pulmonary artery systolic pressure
More informationPerioperative Management of Patients with Obstructive Sleep Apnea. Kalpesh Ganatra,MD Diplomate, American Board of Sleep Medicine
Perioperative Management of Patients with Obstructive Sleep Apnea Kalpesh Ganatra,MD Diplomate, American Board of Sleep Medicine Disclosures. This activity is supported by an education grant from Trivalley
More information2013 ACO Quality Measures
ACO 1-7 Patient Satisfaction Survey Consumer Assessment of HealthCare Providers Survey (CAHPS) 1. Getting Timely Care, Appointments, Information 2. How well Your Providers Communicate 3. Patient Rating
More informationCardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias
Cardiovascular System & Its Diseases Lecture #4 Heart Failure & Cardiac Arrhythmias Dr. Derek Bowie, Department of Pharmacology & Therapeutics, Room 1317, McIntyre Bldg, McGill University derek.bowie@mcgill.ca
More informationDepartment of Pulmonology, Critical Care and Sleep Medicine, Bolan Medical College, Pakistan
Cronicon OPEN ACCESS PULMONOLOGY AND RESPIRATORY MEDICINE Review Article Sleep Apnea Sanaullah Tareen Department of Pulmonology, Critical Care and Sleep Medicine, Bolan Medical College, Pakistan *Corresponding
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationTranscatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators
Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations Danny Dvir, MD On behalf of VIVID registry investigators Introduction Bioprosthetic valves are increasingly implanted in open-heart surgeries.
More informationEffectiveness of Portable Monitoring Devices for Diagnosing Obstructive Sleep Apnea: Update of a Systematic Review
Effectiveness of Portable Monitoring Devices for Diagnosing Obstructive Sleep Apnea: Update of a Systematic Review Submitted to: Agency for Healthcare Research and Quality 540 Gaither Road Rockville, Maryland
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationHelpful hints for filing
Helpful hints f filing Polysomnography Home Sleep Testing (HST) f diagnosing obstructive sleep apnea (OSA) Mary Coughlin RN, MS, NNP, Global Clinical Services Managers, Children s Medical Ventures Sleep
More informationMedicare C/D Medical Coverage Policy
Medicare C/D Medical Coverage Policy Oxygen and Oxygen Supplements Origination: April 10, 1992 Review Date: July 15, 2015 Next Review: July, 2017 DESCRIPTION OF PROCEDURE OR SERVICE USP Oxygen is a gaseous
More informationSLEEP STUDIES AND THERAPY MANAGEMENT
SLEEP STUDIES AND THERAPY MANAGEMENT Effective November 1 st, 2012 Policy NHP has partnered with SMS (Sleep Management Solutions) and their parent company, CareCentrix (CCX) to provide sleep study and
More informationHow do you decide on rate versus rhythm control?
Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study
More informationTitration protocol reference guide
Titration protocol reference guide Description Page Titration protocol goals 4 CPAP protocol CPAP protocol 6 CPAP titration protocol 7 CPAP reimbursement criteria 8 BiPAP S protocol BiPAP S protocol 10
More informationSleep Apnea. ACP Oct 26, 2014. Bashir Chaudhary, MD Sleep Institute of Augusta, Augusta GA
Sleep Apnea ACP Oct 26, 2014 Bashir Chaudhary, MD Sleep Institute of Augusta, Augusta GA Emeritus Professor of Medicine and Assistant Dean of Clinical Affairs, CAHS Medical College of Georgia, Georgia
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationHome Sleep Testing Common Questions and Answers
Home Sleep Testing Common Questions and Answers Suite 1, 100 Schneider Road Kanata, Ontario, Canada K2K 1Y2 Tel: 613.831.6690 Fax: 613.831.6699 braebon.com D.MP8.80200.2 November 2013 I thought BRAEBON
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationPulmonary Artery Hypertension
Pulmonary Artery Hypertension Janet M. Pinson, RN, MSN, ACNP Maureen P. Flattery, RN, MS, ANP Virginia Commonwealth University Health System Richmond, VA Pulmonary artery hypertension (PAH) is defined
More informationManaging Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular Mitral Regurgitation Anatomy Mechanisms of MR Presentation Evaluation Management Repair Replace Clip
More informationDIAGNOSING SLEEP APNEA. Christie Goldsby Florida State University PHY 3109 04/09/14
DIAGNOSING SLEEP APNEA Christie Goldsby Florida State University PHY 3109 04/09/14 Outline of Talk Background information -what is sleep apnea? Diagnosing sleep apnea -polysomnography -respiratory airflow
More informationAdvances in Diagnosis and Treatment of Sleep Apnea Syndrome in Japan
Research and Reviews Advances in Diagnosis and Treatment of Sleep Apnea Syndrome in Japan JMAJ 52(4): 224 230, 2009 Toshiaki SHIOMI,* 1 Ryujiro SASANABE* 2 Abstract The complaint of excessive daytime sleepiness
More informationROLE OF ORAL APPLIANCES TO TREAT OBSTRUCTIVE SLEEP APNEA
1 ROLE OF ORAL APPLIANCES TO TREAT OBSTRUCTIVE SLEEP APNEA There are three documented ways to treat obstructive sleep apnea: 1. CPAP device 2. Oral Appliances 3. Surgical correction of nasal and oral obstructions
More informationLow-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
More informationPractice Parameters for the Indications for Polysomnography and Related Procedures: An Update for 2005
PRACTICE PARAMETER Practice Parameters for the Indications for Polysomnography and Related Procedures: An Update for 2005 Clete A. Kushida, MD, PhD 1 ; Michael R. Littner, MD 2 ; Timothy Morgenthaler,
More informationReport on comparing quality among Medicare Advantage plans and between Medicare Advantage and fee-for-service Medicare
O N L I N E A P P E N D I X E S 6 Report on comparing quality among Medicare Advantage plans and between Medicare Advantage and fee-for-service Medicare 6-A O N L I N E A P P E N D I X Current quality
More information2015 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older)
2015 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older) IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered
More informationOriginal articles. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. C F P George
58 Thorax 21;56:58 512 Original articles Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP C F P George University of Western Ontario, London Health Sciences Centre,
More informationWhat Is the Future of Sleep Medicine? Outline of Talk. Current State of Sleep Medicine. What changed the landscape?
What Is the Future of Sleep Medicine? Allan I. Pack, M.B.Ch.B., Ph.D. The John Miclot Professor of Medicine Division of Sleep Medicine/Department of Medicine Center for Sleep and Circadian Neurobiology
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationOUTCOMES OF CPAP TREATMENT IN A SLEEP LABORATORY SPECIALIZED IN NEUROPSYCHIATRY
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2004, 55, Suppl 3, 15 22 www.jpp.krakow.pl J. ANTCZAK 1,2, P. GEISLER 2, R. POPP 2 OUTCOMES OF CPAP TREATMENT IN A SLEEP LABORATORY SPECIALIZED IN NEUROPSYCHIATRY
More informationItamar Medical Coding and Reimbursement
Itamar Medical Coding and Reimbursement WatchPAT Home Sleep Apnea Testing (HSAT) Frequently Asked Questions DISCLAIMER: The information contained in this guide is provided to assist you in understanding
More informationPulmonary Diseases. Lung Disease: Pathophysiology, Medical and Exercise Programming. Overview of Pathophysiology
Lung Disease: Pathophysiology, Medical and Exercise Programming Overview of Pathophysiology Ventilatory Impairments Increased airway resistance Reduced compliance Increased work of breathing Ventilatory
More informationHeart Failure: Diagnosis and Treatment
Heart Failure: Diagnosis and Treatment Approximately 5 million people about 2 percent of the U.S. population are affected by heart failure. Diabetes affects 20.8 million Americans and 65 million Americans
More information4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts
Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.
More informationVCH PHCTF EVALUATION CORE INDICATORS, DATA COLLECTION PROCESSES, TOOLS & TARGETS
OVERVIEW In alignment with VCH PHCTF deliverables, there is general agreement that our teams use the following core evaluation indicators and evaluation processes to move closer to the proposed targets
More informationPulmonary Hypertension in Sickle Cell Disease. Jorge Ramos Hematology Fellows Conference June 28, 2013
Pulmonary Hypertension in Sickle Cell Disease Jorge Ramos Hematology Fellows Conference June 28, 2013 Patient Presentation 28F with SCD, genotype SS. Presented to UWMC ER with 1 month progressive DOE and
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationNon-Invasive Positive Pressure Ventilation in Heart Failure Patients: For Who, Wy & When?
REUNIÃO CONJUNTA DOS GRUPOS DE ESTUDO DE CUIDADOS INTENSIVOS CARDÍACOS E DE FISIOPATOLOGIA DO ESFORÇO E REABILITAÇÃO CARDÍACA O L H Ã O 2 7 e 2 8 d e J a n e i r o 2 0 1 2 Non-Invasive Positive Pressure
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationEVIDENCE GRADING SYSTEM
I CSI INSTITUTE FOR CLINICAL SYSTEMS IMPROVEMENT EVIDENCE GRADING SYSTEM The evidence grading system used in ICSI guidelines and technology assessment reports is periodically reviewed and modified. The
More informationPerformance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis
Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis Methodology: 8 respondents The measures are incorporated into one of four sections: Highly
More informationSnoring and Obstructive Sleep Apnea (updated 09/06)
Snoring and Obstructive Sleep Apnea (updated 09/06) 1. Define: apnea, hypopnea, RDI, obstructive sleep apnea, central sleep apnea and upper airway resistance syndrome. BG 2. What are the criteria for mild,
More informationAtrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
More informationSLEEP APNEA AND SLEEP Diagnostic aspects. Carin Sahlin
SLEEP APNEA AND SLEEP Diagnostic aspects Carin Sahlin Department of Public Health and Clinical Medicine, Respiratory Medicine and Allergy, Umeå University, Sweden 2009 Umeå University Medical Dissertations
More informationPETER P. LOPEZ, M.D.,» BIANCA STEFAN, M.S.,t CARL L SCHULMAN, M.D.,t PATRICIA M. BYERS, M.D.+
Prevalence of Sleep Apnea in Morbidly Obese Patients Who Presented for Weight Loss Surgery Evaluation: More Evidence for Routine Screening for Obstructive Sleep Apnea before Weight Loss Surgery PETER P.
More informationDISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015
Death (%) Mortality (%) 9/16/2015 DISCLOSURE Atrial Fibrillation Management An Evidence-based Approach Jonathon Adams, MD, FHRS Relevant Financial Relationship(s) None Off Label Usage None OBJECTIVES What
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationEfficacy of daytime continuous positive airway pressure titration in severe obstructive sleep apnoea
Eur Respir J 2001; 18: 535 541 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Efficacy of daytime continuous positive airway pressure titration
More informationOximetry Alone Versus Portable Polygraphy for Sleep Apnea Screening Before Bariatric Surgery
OBES SURG (2010) 20:326 331 DOI 10.1007/s11695-009-0055-9 CLINICAL RESEARCH Oximetry Alone Versus Portable Polygraphy for Sleep Apnea Screening Before Bariatric Surgery Maude Malbois & Vittorio Giusti
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationComparing the Performance and Efficacy of the 3B/BMC RESmart. Auto-CPAP with the ResMed S9 AutoSet
3B MEDICAL, INC., 21301 US HIGHWAY 27, LAKE WALES, FL. 33859 Comparing the Performance and Efficacy of the 3B/BMC RESmart Auto-CPAP with the ResMed S9 AutoSet Zhi Zhuang, PhD, Research and Development,
More informationInpatient Heart Failure Management: Risks & Benefits
Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical
More informationMay 7, 2012. Submitted electronically via www.regulations.gov. Re: CMS 0044 P. Dear Administrator Tavenner:
Marilyn Tavenner Administrator Centers for Medicare and Medicaid Services (CMS) Department of Health and Human Services P.O. Box 8013 Baltimore MD 21244 8013 Submitted electronically via www.regulations.gov
More informationUsing EHRs for Heart Failure Therapy Recommendation Using Multidimensional Patient Similarity Analytics
Digital Healthcare Empowering Europeans R. Cornet et al. (Eds.) 2015 European Federation for Medical Informatics (EFMI). This article is published online with Open Access by IOS Press and distributed under
More informationCARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationHow do you decide on rate versus rhythm control?
How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration
More informationMISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
More information